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A B S T R A C T
The Coenzyme A (CoA), as a cofactor involved in>100 metabolic reactions, is essential to the basic bio-
chemistry of life. Here, we investigated the CoA biosynthetic pathway of Entamoeba histolytica (E. histolytica), an
enteric protozoan parasite responsible for human amebiasis. We identiﬁed four key enzymes involved in the CoA
pathway: pantothenate kinase (PanK, EC 2.7.1.33), bifunctional phosphopantothenate-cysteine ligase/dec-
arboxylase (PPCS-PPCDC), phosphopantetheine adenylyltransferase (PPAT) and dephospho-CoA kinase (DPCK).
Cytosolic enzyme PanK, was selected for further biochemical, genetic, and phylogenetic characterization. Since
E. histolytica PanK (EhPanK) is physiologically important and suﬃciently divergent from its human orthologs,
this enzyme represents an attractive target for the development of novel anti-amebic chemotherapies. Epigenetic
gene silencing of PanK resulted in a signiﬁcant reduction of PanK activity, intracellular CoA concentrations, and
growth retardation in vitro, reinforcing the importance of this gene in E. histolytica. Furthermore, we screened the
Kitasato Natural Products Library for inhibitors of recombinant EhPanK, and identiﬁed 14 such compounds. One
compound demonstrated moderate inhibition of PanK activity and cell growth at a low concentration, as well as
diﬀerential toxicity towards E. histolytica and human cells.
1. Introduction
Coenzyme A (CoA) is an essential cofactor in all living organisms as
an acyl group carrier and carbonyl-activating group involved in more
than 100 cellular reactions (Begley et al., 2001); it is estimated to be a
cofactor used in 9% of identiﬁed enzymatic reactions (Strauss, 2010).
CoA biosynthesis is considered to be an essential and universal pathway
of the majority of prokaryotes and eukaryotes (Leonardi et al., 2005b).
In general, CoA participates in fatty acid metabolism, the tricarboxylic
acid cycle and numerous other intermediary metabolic reactions
(Abiko, 1975). CoA is synthesized from pantothenate (vitamin B5),
cysteine, and ATP (Jackowski, 1996; Leonardi et al., 2005b). Most of
the eukaryotes are unable to synthesize pantothenic acid and thus rely
on an external supply.
Entamoeba histolytica is the protozoan agent responsible for human
amebiasis, an infectious disease causing dysentery and amebic liver
abscesses, responsible for 100,000 deaths annually throughout the
world. It represents the third most common parasitic cause of death,
after malaria and schistosomiasis (Stanley, 2003; Ali and Nozaki, 2007;
Ralston and Petri, 2011). The elaborate pathogenesis of this parasite is
well documented (Espinosa-Cantellano and Martínez-Palomo, 2000;
Nozaki and Bhattacharya, 2015). Metronidazole has, for decades, been
the most eﬀective drug in the treatment of amebiasis despite its known
side eﬀects and low eﬃcacy against asymptomatic cyst carriers.
Moreover, resistance, virulence and host immune response to me-
tronidazole treatment in amebiasis have been reported in some coun-
tries (Griﬃn, 1973; Pittman and Pittmann, 1974; Johnson, 1993; Koch
et al., 1997; Ali and Nozaki, 2007). The molecular target of me-
tronidazole has been well described as a key metabolic enzyme, pyr-
uvate: ferredoxin oxidoreductase, which is involved in acetyl CoA
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production from pyruvate as part of central energy metabolism. Iden-
tiﬁcation and characterization of novel drug targets unique to E. his-
tolytica are therefore needed to design better therapeutics against
amebiasis.
Here we investigate the CoA biosynthetic pathway of E. histoltyica.
We identiﬁed four enzymes, including one bifunctional enzyme, in-
volved in this pathway. We further characterized one of these enzymes,
pantothenate kinase (PanK, EC 2.7.1.33), with biochemical and reverse
genetic approaches. Moreover, we identiﬁed E. histolytica PanK in-
hibitors by screening the Kitasato Natural Products Library against
EhPanK recombinant enzyme. Taken together, we demonstrate that the
CoA biosynthetic pathway, in general, and PanK, speciﬁcally, re-
presents a rational and novel drug target against amebiasis.
2. Materials and methods
2.1. Organisms, cultivation, and chemicals
Trophozoites of E. histolytica clonal strains HM-1: IMSS cl 6 and G3
(Bracha et al., 2006) were maintained axenically in Diamond's BI-S-33
medium at 35.5 °C as described previously (Diamond et al., 1978).
Trophozoites were continuously maintained in mid-log phase after in-
oculation of one-thirtieth to one-twelfth of the total culture volume.
Escherichia coli BL21 (DE3) strain was obtained from Invitrogen
(Carlsbad, CA, USA). Magnesium-free ATP was procured from Dis-
coverX (Fremont, CA, USA). Ni2+-NTA agarose was procured from
Novagen (Darmstadt, Germany). Lipofectamine and geneticin (G418)
were procured from Invitrogen. Chemicals to evaluate metals in PanK
activity assay were procured from Wako (Tokyo, Japan). All other
chemicals of analytical grade were procured from Sigma-Aldrich
(Tokyo, Japan) unless otherwise stated.
2.2. Production of PanK gene-silenced strain
In order to construct a plasmid for epigenetic gene silencing of E.
histolytica (Bracha et al., 2006; Zhang et al., 2011) PanK (EhPanK), a
fragment corresponding to a 430 bp 5′ open reading frame of EhPanK
gene was ampliﬁed by PCR from cDNA using the following primer set
(sense primer, 5′-CAGAGGCCTATGTCTCAACCATCCCATTCT-3′ and
antisense primer, 5′-AATGAGCTCTCTGAAGATTACCAATCCCAT
AAA-3′). These oligonucleotides contained StuI and SacI restriction
sites (shown in bold). The ampliﬁed product was digested with StuI and
SacI, and ligated into the StuI and SacI double digested psAP2-Gunma
construct (Husain et al., 2011) to synthesize a EhPanK gene silencing
plasmid. The G3 strain trophozoites were transformed with an empty
vector as a control and the silencing plasmid was transfected by lipo-
some-mediated transfection as previously described (Nozaki et al.,
1999). Transformants were initially selected in the presence of 1 μg/mL
geneticin gradually increased to 10 μg/mL.
2.3. Reverse transcriptase PCR
RNA was extracted from approximately 1×106 trophozoites of
EhPanK gene silenced (PanK gs) and control transformant strains using
TRIzol reagent (Ambion, Life Technologies) as previously described
(Chomczynski and Mackey, 1995). DNase treatment was performed
using DNase I (Invitrogen) to exclude genomic DNA. RNA quantity was
determined by measuring the absorbance at 260 nm with a NanoDrop
ND-1000 UV–Vis spectrophotometer (NanoDrop Technologies, Wil-
mington, DE, USA). Approximately one μg total RNA was used for cDNA
synthesis using First-Stand cDNA Synthesis (Superscript® III, Invitrogen)
with reverse transcriptase and oligo (dT) primers according to manu-
facturer's instructions. The cDNA product was diluted 10-fold and PCR
reactions were carried out in 50 μl, using the primer pair (Sense primer,
5′-ATGTCTCAACCATCCCATTC-3′ and antisense primer, 5′-TTACATTA
GTTCTTCTTCATACTC-3′). The PCR conditions were: 98 °C, 10 s; 55 °C,
1min; and 72 °C, 1min; 20–25 cycles. The PCR products obtained were
resolved by agarose gel electrophoresis.
2.4. Quantitative real-time (qRT) PCR
Relative levels of steady-state mRNA of the following genes were mea-
sured using qRT-PCR: PanK (EHI_183060), bifunctional phosphopantothe-
nate-cysteine ligase/decarboxylase (PPCS-PPCDC, EHI_164490), phospho-
pantetheine adenylyltransferase (PPAT, EHI_006680), dephospho CoA
kinase 1 and 2 (DPCK1, EHI_040840; and DPCK2, EHI_155780), and RNA
polymerase II gene (EHI_056690) as a control. Each 20 μL reaction con-
tained 10 μL 2X Fast SYBR Green Master Mix (Applied Biosystems, Foster
City, CA, USA), 0.6 μL each of 10 μM sense and antisense primers, 5 μL 10x
diluted cDNA, and nuclease-free water. PCR was performed using the
StepOne Plus Real-Time PCR System (Applied Biosystems, Foster City, CA,
USA) with the following cycling conditions: enzyme activation at 95 °C for
20 s, followed by 40 cycles of denaturation at 95 °C for 3 s and annealing-
extension at 60 °C for 30 s. All reactions were carried out in triplicate, in-
cluding cDNA-minus controls. The amount of the steady-state mRNA of
each target gene was determined by the ΔCt method with RNA polymerase
II as a reference gene (Livak and Schmittgen, 2001). The mRNA expression
level of each gene in the transformant was expressed relative to that in the
control transfected with psAP2.
2.5. Production of whole lysates from E. histolytica trophozoites
Approximately 1×106 trophozoites were harvested 48 h after in-
itiation of culture and washed with 2% glucose in 1X phosphate buﬀer
saline (PBS) three times. Cells were counted and resuspended in 500 μL
homogenization buﬀer (50mM Tris-HCl, pH 7.5, 250mM sucrose,
50mM NaCl) supplemented with 1mM phenylmethylsulfonyl ﬂuoride
(PMSF) and 0.5 mg/mL E-64 (Peptide Institute, Osaka, Japan). Cells
were disrupted mechanically by a Dounce homogenizer and kept on ice
for 30min with intermittent vortexing followed by centrifugation at
500× g for 30min at 4 °C for removing the insoluble cellular debris.
The supernatant, representing total cell lysate, was carefully collected.
Protein concentrations were spectrophotometrically determined by the
Bradford method using bovine serum albumin as a standard as pre-
viously described (Bradford, 1976).
2.6. Enzyme assays and quantitation of CoA in cell lysates
PanK and DPCK activities in the cell lysate were measured with
coupled assays using ADP Hunter™ Plus Assay kit (DiscoverX, US) ac-
cording to the manufacturer's instructions. Brieﬂy, ﬂuorescence in-
tensities were continuously measured to estimate the formation of re-
soruﬁn at 37 °C by excitation at 530 nm and emission at 590 nm in a
25 μL reaction mixture [10mM MgCl2, 15mM HEPES, 20mM NaCl,
1 mM EGTA, 0.02% tween 20, 0.1mg/mL β-globulin, 2 mM pantothe-
nate or 2mM dephospho CoA for PanK or DPCK, respectively, 0.1 mM
ATP, 2 μL of cell lysate (∼5 μg protein)]. Kinetic data were estimated
by curve ﬁtting with the Michaelis–Menten equation using GraphPad
Prism (GraphPad Software Inc., San Diego, USA). This experiment was
repeated three times in triplicate with proteins isolated from two in-
dependent extractions, and kinetic values are presented as the
means ± S.E. for three independent kinetic assays.
Concentrations of CoA in the cell lysate were measured using the
CoA assay kit (BioVision, CA, USA) according to manufacturer's in-
structions. CoA at 0.05–1 nmole was used to produce a standard curve
to determine the amounts of CoA in lysates. Experiment was conducted
in triplicate, and repeated three times on three diﬀerent days.
2.7. Monitoring of growth kinetics
Trophozoite cultures were continuously maintained in mid-log
phase as described previously, and placed on ice for 5min to detach
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cells from the glass surface. Cells were collected by centrifugation at
500× g for 5min at room temperature. After discarding the spent
medium, the pellet was re-suspended in 1mL of BI-S-33 medium. Cell
densities were estimated on a haemocytometer. Approximately 10,000
trophozoites were inoculated in 6mL fresh BI-S-33 medium. Cultures
were examined every 24 h for 5 days.
2.8. Genome-wide survey of enzymes involved in CoA biosynthesis in the E.
histolytica genome
Putative genes encoding PanK, PPCS-PPCDC, PPAT, and DPCK were
identiﬁed in the genome of HM-1:IMSS in the E. histolytica genome
database (AmoebaDB, http://amoebadb.org/amoeba/) using the blastp
online search tool (protein-protein BLAST). Human or bacterial ortho-
logs (Human PanK1α/NP_683878.1, E. coli bifunctional CoaBC/
WP_089667520.1, Human bifunctional COASY/AAL50813.1) retrieved
from non-redundant protein sequences (nr) database of National Center
for Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov/)
were used as query sequences. Pathway analysis was conducted using
Kyoto Encyclopedia of Genes and Genomes database (KEGG, https://
www.genome.jp/kegg). The steady-state mRNA level of each gene in
the trophozoite stage was examined using our previous array data as an
independent experiment in both HM1: IMSS cl6 (Penuliar et al., 2012,
2015) and G3 strains (Nakada-Tsukui et al., 2012; Furukawa et al.,
2012, 2013). Then using Entamoeba invadens orthologs, we compared
the mRNA expression levels of these genes during various timepoints
during the encystation stage (De Cádiz et al., 2013).
2.9. Phylogenetic analysis of PanK
Putative orthologs of PanK from a variety of organisms were re-
trieved by a blastp search of non-redundant protein sequences (nr)
database of National Center for Biotechnology Information (NCBI,
http://www.ncbi.nlm.nih.gov/) using the EhPanK sequence (XP_
001913460) as a query. To comprehensively retrieve all orthologs
from representative organisms in the variety of major taxa, we carried
out a blastp search against each taxonomic group as shown in Table S1.
In each blastp analysis, a list of selected sequences was made with an E-
value less than 1×10−10 in pairwise alignments with EhPanK. Based
on the lists for all taxonomic groups in Table S1, we selected 81 se-
quences as a ﬁnal data set. The Muscle program (Edgar, 2004) in Sea-
View software package version 4.6.1 (Gouy et al., 2010) was used for
sequence alignment. Then 145 unambiguously aligned positions were
selected by manual inspection and used for phylogenetic analyses.
The phylogenic data matrices were subjected to analysis with the
IQTREE program (Nguyen et al., 2015) to select appropriate models for
amino acid sequence evolution. The LG+ Γ4 model was found to be the
best for analysis. Maximum likelihood (ML) analysis implemented in
the RAxML program version 7.2.6 (Stamatakis, 2006) was used to infer
the ML tree by applying LG + Γ4 model. In the bootstrap analysis,
heuristic tree search was performed with a rapid bootstrap algorithm
option (-f) for 100 bootstrap replicates. Bootstrap proportion (BP) va-
lues greater than 50 were indicated on the corresponding internal
branches of the ML tree drawn with FigTree program Version 1.4.2
(http://tree.bio.ed.ac.uk/software/ﬁgtree/).
2.10. Production of E. histolytica transformant line to express Myc-tagged
PanK
The EhPanK gene was ampliﬁed from cDNA using Ex Taq DNA
polymerase (Takara) using the following primer set (sense primer, 5′-
GCCCCGGGATGTCTCAACCATCCCATTC -3′ and antisense, 5′- GCCTC
GAG TTACATTAGTTCTTCTTCATACTC-3′), restriction sites are in-
dicated in bold. An ampliﬁed fragment was ligated into SmaI and XhoI
double digested pEhEx-Myc expression vector (Nakada-Tsukui et al.,
2012) to produce pEhExMyc-PanK. The plasmid was introduced into
trophozoites of E. histolytica HM-1:IMSS cl6 (Diamond et al., 1978) by
liposome-mediated transfection (Nozaki et al., 1999). Transformants
were selected and maintained as described previously.
2.11. Cell fractionation and immunoblot analysis
Trophozoites of the amoeba transformant expressing Myc-EhPanK
and the mock transformant, transfected with pEhEx-Myc, were washed
three times with PBS containing 2% glucose. After resuspension in
homogenization buﬀer (50mM Tris-HCl, pH 7.5, 250mM sucrose,
50mM NaCl and 0.5mg/mL E-64 protease inhibitor), cells were dis-
rupted mechanically by a Dounce homogenizer on the ice, centrifuged
at 500× g for 5min, and the supernatant was collected to remove
unbroken cells. The supernatant fraction was centrifuged at 5000× g
for 10min to isolate pellet and supernatant fractions. The 5000× g
supernatant fraction was further centrifuged at 100,000× g for 60min
to produce a 100,000× g supernatant and pellet fractions. The pellets
at each step were further washed twice with homogenization buﬀer and
re-centrifuged at 100,000× g for 10min to minimize carryover.
Immunoblot analysis was performed using the fractions and anti-Myc
mouse monoclonal antibody. Anti-CPBF1 (cysteine protease binding
family protein 1) and anti-CS1 (cysteine synthase 1) rabbit antisera
were used as organelle membrane and cytosolic markers, respectively.
2.12. Production of EhPanK recombinant protein
The plasmid was constructed as previously described (Sambrook
and Russell, 2001). DNA fragment was ampliﬁed from E. histolytica
cDNA. Primers used were sense, 5′- GCCGGGATCCATGTCTCAACCAT
CCCATTC -3′ and antisense, 5′- GCCG GTCGACTTACATTAGTTCTTCT
TCATACTC-3’. Bold letters indicate BamHI and SalI restriction sites.
PCR was performed with primeSTAR HS DNA polymerase (Takara) and
the following parameters: initial incubation at 98 °C for 30 s; followed
by the 30 cycles of denaturation at 98 °C for 10 s; annealing at 55 °C for
30 s; and elongation at 72 °C for 1min; and a ﬁnal extension at 72 °C for
7min. The PCR fragment was digested with BamHI and SalI, puriﬁed
with Wizard® SV Gel and PCR Clean-up System (Promega). The frag-
ment was cloned into BamHI and SalI double digested pCOLD1™ his-
tidine-tag vector (Takara) to ﬁnally produce pCOLD1-EhPanK. The
nucleotide sequence of the engineered plasmid was veriﬁed by se-
quencing.
pCOLD1-EhPanK was introduced into E. coli BL21(DE3) cells via
heat shock at 42 °C for 1min. E. coli BL21 (DE3) harboring pCOLD1-
EhPanK was grown at 37 °C in 100mL of Luria Bertani medium
(Invitrogen) in the presence of 100 μg/mL ampicillin (Nacalai Tesque).
The overnight culture was used to inoculate 500mL of fresh medium,
and the culture was further continued at 37 °C with shaking at 180 rpm.
When A600 absorbance reached 0.8, then 0.5 mM isopropyl β-D-thio-
galactopyranoside (IPTG) was added, and cultivation was continued for
another 24 h at 15 °C. E. coli cells from the induced culture were har-
vested by centrifugation at 5000× g for 20min at 4 °C. The cell pellet
was washed with PBS, pH 7.4, re-suspended in 20mL of the lysis buﬀer
(50mM Tris HCl, pH 8.0, 300mM NaCl, and 10mM imidazole) con-
taining 0.1% Triton x 100 (v/v), 100 μg/mL lysozyme, and 1mM PMSF,
and incubated at room temperature for 30min. Then the mixture was
sonicated on ice and centrifuged at 25,000× g for 15min at 4 °C. The
supernatant was mixed with 1.2 mL of 50% Ni2+-NTA His-bind slurry,
incubated for 1 h at 4 °C with mild shaking. The recombinant enzyme-
bound resin in a column was washed three times with buﬀer A (50mM
Tris-HCl, pH 8.0, 300mM NaCl, and 0.1% Triton X-100, v/v) con-
taining 10–50mM of imidazole. Bound protein was eluted with buﬀer A
containing 100–300mM imidazole. After the integrity and the purity of
recombinant protein were conﬁrmed with 12% SDS-PAGE analysis,
followed by Coomassie Brilliant Blue staining, the sample was dialyzed
against a 300-fold volume of 50mM Tris-HCl, 150mM NaCl, pH 8.0
containing 10% glycerol (v/v) and the Complete Mini protease
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inhibitor cocktail (Roche, Mannheim, Germany) for 18 h at 4 °C. Pure
enzyme was stored at−80 °C with 20% glycerol in small aliquots until
use.
2.13. Screening of natural compounds for EhPanK inhibitors
We screened 244 compounds from the Kitasato Natural Products
Library for inhibition of EhPanK activity. Initially, each compound was
dissolved in 50% DMSO and water at a ﬁnal concentration of 1mg/mL.
Enzymatic reactions were carried out on a black 384-well microtiter
plate with a 20 μL reaction mixture composed of 19 μl enzyme mix
(100 μM pantothenate, 100 μM ATP, 50 ng of EhPanK recombinant
enzyme in kinase buﬀer (see above) and 1 μl of the individual com-
pounds (ﬁnal concentration 50 μg/mL or 25–200 μM) at 37 °C for 2 h.
After the kinase reaction, ADP was measured using ADP Hunter™ Plus
kinase assay kit as described previously. Inhibition values were mea-
sured in triplicate.
Compounds that showed more than 50% inhibition at< 400 μM
were re-tested to conﬁrm that they did not inhibit the enzyme in the
coupled assay (pyruvate kinase and pyruvate oxidase) in ADP Hunter™
Plus kinase assay kit. Inhibition of the enzymes used in the coupled
assay was examined in the reaction mixture (10mM MgCl2, 15mM
HEPES, 20mM NaCl, 1 mM EGTA, 0.02% tween 20, 0.1 mg/mL β-glo-
bulin, 60 μM pantothenate, 50 μM ATP, 10–50 μM ADP, and 25–200 μM
of selected active compounds). No signiﬁcant change was observed in a
range of ADP and inhibitor concentrations, suggesting no inhibition of
coupled enzymes by the EhPanK inhibitors. Compounds that did not
inhibit enzymes used in the coupled assay were selected as hits for
further evaluation, including dose-response, determination of con-
centration needed for 50% inhibition (IC50) of PanK activity as well as
both E. histolytica and human cell growth.
2.14. Measurement of anti-amebic activity of EhPanK inhibitor compounds
Approximately 1×104 trophozoites of E. histolytica clonal strain
HM-1:IMSS cl6 in 200 μl of BI-S-33 medium were dispensed into each
well of a 96-well plate and incubated at 35.5 °C for 2 h. Medium was
then removed and replaced with 200 μl of BI-S-33 medium that con-
tained various concentrations of each compound. The ﬁnal concentra-
tions of test compounds are 50–600 μM for cephaloridine, hygromycin
A, erythromycin A, and ﬂuorescamine; 5–200 μM for kasugamycin,
gardimycin, rosamycin, streptomycin, tirandamycin A, neomycin, and
teicoplanin; 0.1–10 μM for O-methylnanaomycin A, echinomycin, and
trichostatin. The plate was incubated under anaerobic conditions at
35.5 °C for 48 h. After the medium was removed, 100 μl of pre-warmed
Opti-MEM I (Life Technologies, Grand Islands, NY, USA) containing
one-tenth volume of WST-1 (Roche, Mannheim, Germany) was added.
The viability of trophozoites was estimated by measuring absorbance at
450 nm by SpectraMax® Paradigm® (Molecular Devices, CA, USA).
Metronidazole was used as positive control at ﬁnal concentrations of
0.1–10 μM and 0.5% DMSO as negative control. Each assay was per-
formed in triplicate. IC50 values were calculated by least squares curve
ﬁtting of the dose inhibition curves using GraphPad Prism (GraphPad
Software Inc., San Diego, USA).
2.15. Evaluation of cytotoxicity against MRC-5 cells
Human ﬁbroblast cells, MRC-5, were cultured on 96-well ﬂat
bottom plates at a density of 1.5× 104 cells/well with 100 μl of MEM
medium (Life Technologie) containing 10% fetal bovine serum (Hana-
nesco Bio, Tokyo, Japan) and 1% penicillin-streptomycin (Life
Technologies). Cells were incubated at 37 °C with 5% CO2 for 48 h.
Approximately 100 μl of MEM medium containing 5 μl of each com-
pound dissolved in 50% DMSO in water were added to each well. After
the plates were incubated for 48 h, approximately 10 μl of WST-8
(Dojindo, Kumamoto, Japan) was added to each well and the plate was
incubated at 37 °C with 5% CO2 for 2 h. The absorbance was measured
at 450 nm by spectrophotometer (SH-9000Lab, Corona Electric, Ibaraki,
Japan). Growth of MRC-5 cells was measured in duplicate.
Staurosporine (Kitasato Natural Products Library) was used as a
Fig. 1. Coenzyme A biosynthetic pathway in E. histolytica. ID numbers of individual enzymes in AmoebaDB are also shown. PanK, pantothenate kinase; PPCS-PPCDC, bifunctional
phosphopantothenoylcysteine synthetase and phosphopantothenoylcysteine decarboxylase; PPAT, phosphopantetheine adenylyltransferase; and DPCK, dephosphocoenzyme A kinase.
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positive (cytotoxic) control in a concentration range of 0.5 pM to
0.1 nM IC50 values were calculated as described previously.
3. Results
3.1. Identiﬁcation of four enzymes involved in CoA biosynthesis in E.
histolytica
We identiﬁed all putative genes involved in CoA biosynthesis in the
reference genome of E. histolytica: HM-1:IMSS (Fig. 1). Four genes en-
coding sequential pathway enzymes were identiﬁed: pantothenate ki-
nase (EC 2.7.1.33, PanK), bifunctional phosphopantothenate-cysteine
ligase/decarboxylase (EC 6.3.2.5/EC 4.1.1.36), phosphopantetheine
adenylyltransferase (EC 2.7.7.3), and dephospho CoA kinase (EC
2.7.1.24). We identiﬁed a single putative PanK gene in each strain (e.g.,
EHI_183060 in HM-1:IMSS and EHI7A_012650 in HM-1:IMSS-A) in
Amoeba Genomics Resources database, AmoebaDB (http://amoebadb.
org). The nucleotide sequences of the genes in diﬀerent strains are
100% identical. Therefore, E. histolytica seems to have only one PanK
gene.
Our previous transcriptome data veriﬁed that all four genes are
expressed at low to moderate levels (Fig. S1A). The level of mRNA
expression relative to RNA polymerase for PanK, PPCS-PPCDC, PPAT,
DPCK1, and DPCK2 in trophozoites of the E. histolytica clonal strain
HM1: IMSS cl6 (Penuliar et al., 2015, 2012) and G3 (Nakada-Tsukui
et al., 2012; Furukawa et al., 2012, 2013) strain were 1.2–1.8, 0.5–0.6,
0.3–0.4, 0.04–0.05 and 0.3–0.4, respectively. In this research, we de-
scribe biochemical and genetic characterization of PanK; investigation
of other enzymes involved in CoA biosynthesis will be described else-
where. Our previous transcriptomic analysis of E. invadens (De Cádiz
et al., 2013), as a model for encystation (Donaldson et al., 1975;
Kojimoto et al., 2001; Stanley, 2003; Chia et al., 2009), showed that
genes encoding these four enzymes were expressed during encystation,
but the expression proﬁles of individual enzymes largely diﬀered (Fig.
S1B). The expression proﬁles of PPCS-PPCDC and DPCK1 were quite
peculiar with expression peaking at certain time points (2 h and 24 h,
respectively); this subject was, however, not investigated as part of this
study.
3.2. Features of EhPanK and its encoded protein
The 1219-bp E. histolytica PanK gene contains two small introns, and
is predicted to encode a 403 a.a. polypeptide with a molecular mass of
45.2 kDa and a pI value of 5.2. EhPanK showed 99, 96, 83, and 70%
sequence identity to PanK from E. nuttalli, E. dispar, E. moshkovskii, and
E. invadens, respectively. In general, PanK is classiﬁed into three groups,
type I through III, as determined by primary sequence analysis and
kinetic properties (Song and Jackowski, 1993; Rock et al., 2002; Yang
et al., 2006). E. histolytica PanK is classiﬁed as PanK type II, and shows a
low level (∼35%) of positional identity to the A. thaliana and human
orthologs, both of which also belong to type II (Fig. S2 and S3). When
compared to human PanK, Entamoeba PanK shows the highest similarity
to human PanK4 (35%), whereas similarity to other human PanK iso-
types (PanK1α, PanK1β, PanK2, and PanK3) is ∼32%. All amino acid
residues were inferred to be involved in pantothenate and ATP catalysis
and substrate binding include the typical ATP-binding motif have been
reported in human PanK1 and PanK3 (Bum et al., 2007). Some con-
served glycine residues in the ATP binding motif (Gly19 and Gly321 in
human PanK3; Gly59 and Gly351 in E. histolytica) are indispensable for
activity. Mutations of this amino acid have been demonstrated to
abolish enzymatic activity because ATP is no longer able to properly
bind (Bum et al., 2007). Furthermore, it is understood that phosphor-
ylation is proceeded by an ordered sequential mechanism, with ATP
binding preceding pantothenate binding (Leonardi et al., 2005a).
3.3. Phylogenetic analysis of EhPanK
We determined the phylogenetic relationship between 81 putative
PanK orthologs collected from bacteria and eukaryotes (Table S1, Fig.
S2). The majority of eukaryotes possess the PanK gene. Mammals
(Opisthokonta) and land plants (Viridiplantae) apparently possess twice
or more two genes. For instance, four PanK genes were identiﬁed from
Homo sapiens, PanK1α and PanK1β (Rock et al., 2002), PanK2 (anno-
tated as a mitochondrial precursor protein) (Hörtnagel et al., 2003;
Kotzbauer et al., 2005), and PanK3 (Zhang et al., 2005). Archaea and
most bacterial groups do not possess PanK homologs that show simi-
larity to EhPanK with the E-value less than 10−10. PanK homologs were
identiﬁed, however in Firmicutes, speciﬁcally Bacilli. During sequence
alignment, only the ‘fumble’ domain (PFAM:PFO03630) could be
aligned among all 81 sequences, although insertions and deletions were
needed for proper alignment due to a high degree of divergence. PanKs
from Euglenozoa have an∼1000-a.a. long N-terminal extension, which
contains an exonuclease-endonuclease-phosphatase (EEP) domain in
the 300 a.a.-long N-terminal region and a 550 a.a.-long adenylate
forming (AF) domain. Some of PanK from Viridiplantae have a 300 a.a.-
long C-terminal extension, annotated as DUF89 (Domain of Unknown
Function 89) (Huang et al., 2016). PanK from other organisms in-
cluding the genus Entamoeba basically contain only a ‘fumble’ domain;
neither the EEP/AF nor DUF89 domain is present in PanK from other
organisms except that some possess an N-terminal extension that ap-
pears to be an organelle targeting sequence.
Based on 145 aligned positions from the ‘fumble’ domain, an op-
timal ML tree was created with bootstrap proportion (BP) support va-
lues (Fig. S2). Eukaryotes and Firmicutes were separated clearly with a
100% BP support value. The Eukaryota clade had monophylies of
several taxonomic groups reconstructed, but BP values were generally
low except for those of Viridiplantae monophyly (88%) and Hapto-
phyceae monophyly (97%). Four Entamoeba species are monophyletic
with 100% BP support, and the Entamoeba clade shares a sister group
position to the clade of Euglenozoa. However, since BP support values
for deep branching patterns were very low, monophyly of Amoebozoa
including the Entamoeba clade cannot be ruled out. Although this
analysis could not precisely infer the phylogenetic position of the En-
tamoeba PanK, it is apparently of a eukaryotic origin.
3.4. Expression and puriﬁcation of recombinant PanK
A soluble EhPanK recombinant protein with a 2.6 kDa histidine tag
at the amino terminus was successfully produced using the pCOLD I E.
coli expression system and puriﬁed to homogeneity (> 95% as eval-
uated with Coomassie Brilliant Blue stained SDS-PAGE gel) (Fig. S4A,
Table S2). Immunoblot analysis of the puriﬁed recombinant protein
using His-Tag antibody conﬁrmed the absence of truncation (Fig. S4B).
The molecular mass of the puriﬁed protein under reducing conditions
was consistent with the predicted molecular mass 45.2 kDa excluding
the histidine tag. The speciﬁc activity of the puriﬁed enzyme was es-
timated to be 1.5 μmol/min/mg when assayed under the standard
conditions described in the “Materials and methods” section. EhPanK is
robust and catalytically active in broad pH range with maximum ac-
tivity obtained at pH 6 and 37 °C (Fig. S5A).
3.5. Kinetic properties and phosphoryl donor speciﬁcities of EhPanK, and
eﬀects of metal ions on EhPanK
Table 1 summarizes the apparent Km, Vmax, and Kcat values for Eh-
PanK using pantothenate and ATP as substrates. EhPanK exhibited
hyperbolic saturation kinetics when assayed over the substrate range of
4–256 μM for pantothenate in the presence of 25–100 μM ATP (Fig.
S5B) and 1–100 μM ATP in the presence of 8–128 μM pantothenate (Fig.
S5C). The apparent Km value for pantothenate at saturating ATP con-
centrations was 53.2 ± 7.1 μM, and the Km value for ATP at saturating
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pantothenate concentrations was 41.4 ± 3.9 μM.
EhPanK utilized various nucleoside triphosphates, ATP, CTP, GTP,
UTP, dATP, and polyphosphates, as well as deoxynucleotides as phos-
phoryl donors, with ATP being the best phosphate donor (Table 2).
EhPanK showed an absolute requirement for a free bivalent metal co-
factor, with Mg2+ as the preferred cation (Table 3).
3.6. Regulation of EhPanK by CoA, acetyl CoA, and malonyl CoA
PanK from other organisms was reported to be negatively regulated
by allosteric inhibition with CoA, acetyl CoA, and malonyl CoA (Calder
et al., 1999; Takagi et al., 2010; Vallari et al., 1987). Similarly, EhPanK
was also inhibited by CoA and its derivatives, although relatively higher
concentrations were needed for inhibition compared with PanK from
other organisms (Brand and Strauss, 2005; Calder et al., 1999) (Fig. 2).
Double-reciprocal plots revealed the mechanisms of inhibition by CoA
and malonyl CoA are competitive with ATP, while inhibition by CoA
and malonyl CoA are uncompetitive or non-competitive with pan-
tothenate, respectively. The mechanisms of inhibition by acetyl CoA
were not clear but seemed to be the mixed type with respect to ATP and
pantothenate (Fig. 3).
3.7. Cellular localization of EhPanK
To examine the localization of EhPanK, we performed fractionation
and immunoblot analysis of PanK using E. histolytica transformant-ex-
pressing Myc-tagged EhPanK. We demonstrated that EhPanK is ex-
clusively present in the 100,000× g supernatant fraction corre-
sponding the cytosol (Fig. S6).
3.8. Eﬀects of EhPanK gene silencing on growth, cellular CoA levels, and
gene expression of the CoA biosynthetic pathway
To investigate the physiological importance and essentiality of PanK
in E. histolytica, we created and examined an E. histolytica strain where
EhPanK was silenced by antisense small RNA-mediated transcriptional
gene silencing (Mirelman et al., 2008); EhPanK gene expression was
successfully silenced (Fig. 4A). The level of silencing was estimated to
be approximately 85% by qRT-PCR measurement. Interestingly, the
steady-state transcript of the genes encoding other enzymes involved in
CoA biosynthesis were up-regulated 1.2 ± 0.03, 2.1 ± 0.2, 3 ± 0.1,
and 5.2 ± 1.0-fold for PPCS-PPCDC, PPAT, DPCK1, and DPCK2, re-
spectively (Fig. 4B).
In order to determine whether the protein level also increased, we
measured PanK and DPCK activity in cell lysates. PanK activity de-
creased by approximately 81% in the EhPanK-silenced strain compared
to the control. In contrast, DPCK activity increased 2.1 fold (Fig. 4C).
CoA concentration decreased by approximately 40% in EhPanK-si-
lenced strain compared to the control (Fig. 4D). Growth kinetic analysis
also showed that in EhPanK-silenced strain showed remarkable growth
retardation as the cell density of EhPanK-silenced strain decreased to
approximately 30–52% of the control at 48–96 h, respectively (Fig. 4E,
Fig. S7A, Fig. S7B).
3.9. Identiﬁcation of EhPanK inhibitors from Kitasato Natural Products
Library
Based on the signiﬁcant biological role of EhPanK, inhibitors of this
enzyme should be considered to possess properties needed for novel
anti-amoebic agents. Therefore, we conducted enzyme-based screening
of the Kitasato Natural Products Library composed of 244 structurally
elucidated compounds using recombinant EhPanK to identify potential
PanK inhibitors. We identiﬁed 14 compounds (Fig. 5) that demon-
strated an IC50 value of< 400 μM (Table 4, Fig. S8). Among these
compounds, Teicoplanin had the best inhibitory activity against Eh-
PanK with an IC50 value of 26.3 ± 2.6 μM. All EhPanK inhibitors also
inhibited E. histolytica trophozoites although the IC50 values of most of
the identiﬁed EhPanK inhibitors were high. Six compounds, O-me-
thylnanaomycin A, Echinomycin, Tirandamycin A, Neomycin, Tri-
chostatin, and Teicoplanin, showed the IC50 values of< 20 μM against
E. histolytica trophozoites, but the IC50 values of O-methylnanaomycin
A, Echinomycin, Tirandamycin A, Neomycin, and Trichostatin against
E. histolytica trophozoites were lower than their IC50 values against
EhPanK activity, suggesting that the target of these compounds for
growth inhibition are unlikely to be through PanK inhibition. In con-
trast, Teicoplanin demonstrated comparable IC50 values against PanK
activity and E. histolytica growth (Table 5).
Table 1
Kinetic parameters of E. histolytica pantothenate kinase.
Substrate Km (μM) Vmax (μmole/
min/mg)
Kcat (min−1) Kcat/Km
(min−1μM−1)
Pantothenate 53.2 ± 7.1 2.79 ± 0.1 126.8 ± 4.5 2.38 ± 0.08
ATP 41.4 ± 3.9 2.84 ± 0.2 129.1 ± 9.2 3.11 ± 0.22
Mean ± SEM of three replicates are shown.
Table 2
Phosphoryl donor speciﬁcity of E. histolytica pantothenate kinase.
Phosphoryl donora Relative activity
(%)
Phosphoryl donora Relative
activity (%)
ATP 100.0 ± 4.1 CTP 1.4 ± 0.2
GTP 78.8 ± 4.9 Metaphosphate ND
dATP 19.3 ± 4.3 Hexametaphosphate ND
Tripolyphosphate 16.9 ± 0.8 Trimetaphosphate ND
UTP 16.6 ± 1.2 Glucose-6-phosphate ND
Polyphosphate 16.2 ± 2.5 Phosphoenolpyruvate ND
TTP 5.4 ± 1.9 None ND
Assays were performed as described in Materials and methods, in the presence 15mM
HEPES, 20mM NaCl, 10mM MgCl2, 1 mM EGTA, 0.02% Tween-20, 0.1 mg/mL
β−globulins and 0.2mM pantothenate. Reactions were conducted at 37 °C at pH 6.
The activity is shown in percentage (%) relative to that toward ATP.
ND, not detected.
Mean ± SEM of three replicates are shown.
a The ﬁnal concentration used was 100 μM.
Table 3
Eﬀect of metal ions on the activity of E. histolytica pantothe-
nate kinase.
Metala Relative activity (%)
MgCl2 100.0 ± 0.0
CuCl2 84.3 ± 4.7
MnCl2 83.2 ± 2.0
CoCl2 74.2 ± 6.1
FeCl2 72.8 ± 1.7
LiCl2 34.5 ± 1.8
CaCl2 17.0 ± 3.0
ZnCl2 3.9 ± 0.7
NiCl2 ND
NaCl ND
KCl ND
None ND
Assays were performed as described in Materials and
methods, in the presence of 100mM ATP, 15mM HEPES,
20mM NaCl, 1 mM EGTA, 0.02% Tween-20, 0.1mg/mL
β−globulins and 0.2mM pantothenate. Reactions were con-
ducted at 37 °C at pH 6.0.
The activity is shown in percentage (%) relative to that to-
ward MgCl2. ND, not detected.
Mean ± SEM of three replicates are shown.
a The cation ﬁnal concentration used was 5mM.
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4. Discussion
4.1. Identiﬁcation of CoA biosynthesis as rational drug target
CoA is an essential and ubiquitous cofactor functioning as an acyl
carrier as well as a carbonyl activating group for many metabolic re-
actions. In the present study, we identiﬁed four enzymes that are in-
volved in CoA synthesis in E. histolytica (Fig. 1) and characterized the
ﬁrst rate-limiting enzyme in this process, PanK. We have provided
evidence for the pivotal role of this enzyme in cell proliferation by gene
silencing.
Since all genes involved in CoA biosynthesis are transcribed in all
amoeba life cycle stages, this pathway is the good target not only for
killing the pathogenic trophozoites but inhibiting stage conversion and
thus amoeba transmission. The mechanism coordinating gene expres-
sion regulation among the ﬁve genes involved in E. histolytica CoA
biosynthesis remains elusive. However, based on our previous tran-
scriptomic analysis of E. invadens, a related reptilian amoeba species
that also causes an invasive disease and has been used as a model
system for E. histolytica (Donaldson et al., 1975; Kojimoto et al., 2001;
Chia et al., 2009) during encystation (De Cádiz et al., 2013), we found
that PanK is transcribed in both trophozoite and encystation life cycle
stages at comparable levels, suggesting that PanK is required in both
stages.
A EhPanK gene-silenced strain was successfully established, after
producing a strain in which EhPanK gene expression was ∼85% re-
pressed. Four failed attempts to create of such a cell line (data not
shown) suggest the essentiality of this gene. The low levels of EhPanK in
our experiment can keep the cells viable, consistent with the previous
publication in Mycobacterium tuberculosis PanK (Reddy et al., 2014).
Interestingly, EhPanK gene silencing resulted in the simultaneous
transcriptional up-regulation of genes for downstream CoA pathway
enzymes. Remarkably, such genes, DPCK1 and DPCK2, were up-regu-
lated 3- and 5-fold, respectively. This observation is similar to that in
experimentation with Plasmodium yoelii, where other genes in the CoA
biosynthetic pathway were up-regulated when PanK2 gene was
knocked out (Hart et al., 2016). Despite the apparent compensatory
upregulation of downstream enzyme genes, CoA concentration was
signiﬁcantly reduced, which is most likely a direct cause of decreased
ATP generation and retarded growth.
In order to validate EhPanK as the drug target, there should be
notable biochemical, structural, and genetic diﬀerences in their human
homologs. Such characteristics should, in theory, minimize toxic side
eﬀects of pharmacological inhibition of human enzymes via amebiasis
chemotherapy. E. histolytica has one PanK enzyme whereas Homo sa-
piens has ﬁve PanK isoforms encoded by four genes. EhPanK is most
closely related to human PanK4 with 35% amino acid identity, but
phylogenetic analyses suggest a distant relationship between EhPanK
and its human counterparts.
While PanK is indispensable for the optimal growth of E. histolytica
trophozoites, but in some eukaryotes, including human, PanK was
shown non-essential. It has been demonstrated that human cells have
the ability to hydrolyze exogenous CoA to 4′-phosphopantetheine by
ectonucleotide pyrophosphatase, and then incorporate 4′-phospho-
pantetheine and enzymatically convert it back to CoA by the bifunc-
tional enzyme CoA synthase (Srinivasan et al., 2015). In Plasmodium, it
was reported that PanK is nonessential in blood stage parasite devel-
opment, but essential in the hepatic stage, as well as oocyst and spor-
ozoite formation in the mosquito (Hart et al., 2016; Srivastava et al.,
2016). In M. tuberculosis, CoaA was proven to be an essential enzyme
(Awasthy et al., 2010), but was also shown in in vitro and in vivo studies
to be a suboptimal target for antimycobacterial drug development be-
cause expression of CoaA gene needs to be repressed to obtain suﬃcient
cidal eﬀects by inhibitors (Reddy et al., 2014). On the other hand,
CoaBC, a bifunctional enzyme in the CoA biosynthesis, has proven to be
essential, but its suitability as drug target needs to be chemically vali-
dated in future (Evans et al., 2016). Inhibition of PanK in human cells
may be tolerated, which also supports the premise that PanK is a rea-
sonable chemotherapeutic target against pathogens for humans.
4.2. Hit discovery of EhPanK inhibitors
Historically, natural products, especially secondary metabolites,
have provided various drugs against human diseases (Newman and
Cragg, 2012). Our group has recently discovered several natural com-
pounds from fungi and actinomycetes that inhibit cysteine synthase, an
enzyme absent in humans and involved in de novo biosynthesis of L-
cysteine (Mori et al., 2015). In this study, we identiﬁed 14 inhibitors of
EhPanK; half of the inhibitors have sugar moieties, and some of them
are aminoglycosides.
Fig. 2. Eﬀect of CoA, acetyl CoA, and malonyl CoA on the
pantothenate kinase activities. Relative activities of EhPanK
in the presence of various concentrations of inhibitors to
those without inhibitors are shown. The assay was per-
formed in 10mMMgCl2, 15mM HEPES, 20mM NaCl, 1mM
EGTA, 0.02% Tween-20, 0.1mg/mL γ−globulins, 0.2 mM
pantothenate, and 100 μM ATP with various concentrations
of CoA, acetyl CoA, or malonyl CoA at 37 °C at pH 6. The
assays were carried out three times independently, and the
results are shown as means ± SEM of triplicates.
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Teicoplanin showed moderate inhibitory activity with IC50
26.3 ± 2.6 μM and inhibition of E. histolytica trophozoite growth (IC50
15.1 ± 2.3 μM). Although Teicoplanin also demonstrated cytotoxicity
to MRC-5 cells, preference towards E. histolytica cells was identiﬁed.
Teicoplanin is a mixture of glycopeptide antibiotics used against Gram-
positive bacteria including methicillin-resistant Staphylococcus aureus,
with a mechanism of action inhibiting bacterial cell wall synthesis.
Teicoplanin consists of the glycopeptide core, two carbohydrates
(mannose and N-acetylglucosamine), and a side chain. The components
of teicoplanin are classiﬁed by their side chain length and conforma-
tion; the major components are A2-1 through A2-5.
In conclusion, we have shown that pantothenate kinase and CoA
biosynthesis are physiologically important for this parasite. We have
also shown that potential EhPanK inhibitors were identiﬁed by
screening the natural product library, suggesting that the enzyme can
be a new target for the development of anti-amebic drugs.
Fig. 3. Double-reciprocal plots of the recombinant EhPanK in the presence of CoA (A and B), malonyl CoA (C and D), or acetyl CoA (E and F). The enzymatic activities were determined
with various concentrations of ATP and 0.2mM pantothenate (A, C, and E) or various concentrations of pantothenate and 100 μM ATP (B, D, and F), in the presence of three con-
centrations of inhibitors (0, 0.5, and 2mM). Data are shown in means ± SEM of triplicate analyses.
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Fig. 4. Analyses of EhPanK gene silenced strain. A) RT-PCR analysis of EhPanK gene transcript from E. histolytica transformants. “psAP” indicates control strain transfected with psAP-2-
Gunma empty vector, and “PanK gs” indicates EhPanK gene silenced strain. B) Relative levels of gene transcripts encoding all four enzymes involved in CoA biosynthesis by qRT-PCR
analysis in psAP and Pan Kgs transformants. qRT-PCR data were normalized against RNA polymerase II, and are shown in percentage relative to the transcript level of each gene in psAP
control. C) PanK and DPCK activity in cell lysates of psAP and PanKgs transformants. D) CoA concentration in cell lysates. For B-D, data are shown in mean ± SEM of three biological
replicates. Statistical comparison is made by Student's t-test (*P < 0.05, **P < 0.01). E) Growth kinetic of E. histolytica transformants during 96 h incubation in BI-S-33 medium. Data
are shown in mean ± SEM of three replicates. Data from one representative experiment of three conducted independently are shown. Statistical comparison is made by Student's t-test
(*P < 0.05, **P < 0.01).
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Fig. 5. Structures of EhPanK inhibitors identiﬁed in this study.
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